FDA approves Watson’s ANDA for lidocaine topical patch 5%

Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc., has received final approval from the United States Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for lidocaine topical patch 5%, the generic equivalent to Endo's Lidoderm®. Watson plans to launch the product in September of 2013 pursuant with its settlement agreement with Endo Pharmaceuticals Inc. and believes that under Hatch Waxman rules, it will be entitled to 180 days of marketing exclusivity.

On May 29, 2012, Watson announced it had entered into an agreement with Endo Pharmaceuticals Inc. and Teikoku Seiyaku Co., Ltd to settle all outstanding patent litigation related to Watson's generic version of Lidoderm®. The agreement allows Watson to launch its lidocaine topical patch 5% product on September 15, 2013.

For the twelve months ending June 30, 2012, Lidoderm® had total U.S. sales of approximately $1.2 billion according to IMS Health data.


Watson Pharmaceuticals, Inc.

Posted in: Pharmaceutical News

Tags: , , , ,



  1. David Marino David Marino United States says:

    The new Watson patch is the worst patch that I have ever had to place on my back. I'm not uncoordinated in the least but if no one helps me put this patch on it takes 3 or 4 trys. What kind of savings is that overall effect is weaker, does not stay on for 12 hours. Good god do they even test this crap obviously not in this case. Biggest waste of money ask doc for a DAW script.

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment